ReviewJournal of the American Society of Nephrology : JASN2017
Moving Biomarkers toward Clinical Implementation in Kidney Transplantation.
Review in Journal of the American Society of Nephrology : JASN, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.
- Development and validation of urinary exosomal microRNA biomarkers for the diagnosis of acute rejection in kidney transplant recipients.Frontiers in immunology · 2023Pooled it
- The applications of DNA methylation as a biomarker in kidney transplantation: a systematic review.Clinical epigenetics · 2022Pooled it
- Circulating cell-free nucleosomes as biomarker for kidney transplant rejection: a pilot study.Clinical epigenetics · 2021Trial
- Human biomarker navigator.iMeta · 2026Review
- Exfoliated kidney cells from urine for non-invasive kidney transplant monitoring: A potential opportunity?Clinical and experimental nephrology · 2026Review
- Elevated Serum Nardilysin Is Inversely Associated with Cardiovascular Disease in Kidney Transplant Recipients.Kidney & blood pressure research · 2026Article
- Detection of Kidney Allograft Rejection Using Urinary Chemokines.Journal of the American Society of Nephrology : JASN · 2025Article
- Implantable bioelectronics and wearable sensors for kidney health and disease.Nature reviews. Nephrology · 2025Review
- Biomarkers of Rejection in Kidney Transplantation.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2025Review
- Advancements in noninvasive techniques for transplant rejection: from biomarker detection to molecular imaging.Journal of translational medicine · 2025Review
- Frailty and sarcopenia metabolomic signatures in kidney transplant candidates: the FRAILMar study.Clinical kidney journal · 2025Article
- Cell-free DNA for the detection of kidney allograft rejection.Nature medicine · 2024Observational
- Design, cohort profile and comparison of the KTD-Innov study: a prospective multidimensional biomarker validation study in kidney allograft rejection.European journal of epidemiology · 2024Article
- Contemporary Biomarkers for Renal Transplantation: A Narrative Overview.Journal of personalized medicine · 2023Review
- Biomarkers for dementia in Latin American countries: Gaps and opportunities.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023Article
- Editorial: Innate immunity and renal transplantation.Frontiers in immunology · 2023Article
- Noninvasive Diagnosis of Acute Rejection in Renal Transplant Patients Using Mass Spectrometric Analysis of Urine Samples: A Multicenter Diagnostic Phase III Trial.Transplantation direct · 2022Article
- Pretransplant endotrophin predicts delayed graft function after kidney transplantation.Scientific reports · 2022Article
- Risk Factors of Rejection in Renal Transplant Recipients: A Narrative Review.Journal of clinical medicine · 2022Review
- Biomarkers of alloimmune events in pediatric kidney transplantation.Frontiers in pediatrics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Long-term kidney transplant outcomes remain suboptimal, delineating an unmet medical need. Although current immunosuppressive therapy in kidney transplant recipients is effective, dosing is conventionally adjusted empirically on the basis of time after transplant or altered in response to detection of kidney dysfunction, histologic evidence of allograft damage, or infection. Such strategies tend to detect allograft rejection after significant injury has already occurred, fail to detect chronic subclinical inflammation that can negatively affect graft survival, and ignore specific risks and immune mechanisms that differentially contribute to allograft damage among transplant recipients. Assays and biomarkers that reliably quantify and/or predict the risk of allograft injury have the potential to overcome these deficits and thereby, aid clinicians in optimizing immunosuppressive regimens. Herein, we review the data on candidate biomarkers that we contend have the highest potential to become clinically useful surrogates in kidney transplant recipients, including functional T cell assays, urinary gene and protein assays, peripheral blood cell gene expression profiles, and allograft gene expression profiles. We identify barriers to clinical biomarker adoption in the transplant field and suggest strategies for moving biomarker-based individualization of transplant care from a research hypothesis to clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.